Assembly Biosciences ASMB Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Assembly Biosciences's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Assembly Biosciences's additional paid-in capital?
- Assembly Biosciences (ASMB) reported additional paid-in capital of $1.04B in Q1 2026.
- How has Assembly Biosciences's additional paid-in capital changed year-over-year?
- Assembly Biosciences's additional paid-in capital increased by 20.6% year-over-year, from $862.12M to $1.04B.
- What is the long-term trend for Assembly Biosciences's additional paid-in capital?
- Over 5 years (2020 to 2025), Assembly Biosciences's additional paid-in capital has grown at a 7.0% compound annual growth rate (CAGR), from $742.39M to $1.04B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.